<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34185cf5-94da-7039-e063-6394a90a9133"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">PHENAZOPYRIDINE HYDROCHLORIDE TABLETS, USP</content>
      <content styleCode="bold"/>
      <br/>
      <br/>
      <content styleCode="bold">Rx Only</content>
   </title>
   <effectiveTime value="20250501"/>
   <setId root="1522921b-d6c2-420d-ba0d-39ac16ba8b37"/>
   <versionNumber value="16"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
            <name>PD-Rx Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
                  <name>PD-Rx Pharmaceuticals, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
                        <name>PD-Rx Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72789-362" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34184d2e-247e-04b3-e063-6294a90a7d5f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250501"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72789-362" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phenazopyridine Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phenazopyridine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="65162-681" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U076Q6Q621" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 1000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0EWG668W17" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENAZOPYRIDINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K2J09EMJ52" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENAZOPYRIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="6" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72789-362-06" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110201"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="brown" xsi:type="CE">
                              <originalText>MAROON</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PY;1</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_c87ca395-0827-41c0-a28e-25060dd8b6ae">
               <id root="34185cf5-94db-7039-e063-6394a90a9133"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">CAUTION:</content>Federal law prohibits dispensing without prescription.

 </paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_644df5e9-136a-4a58-8a4b-fc4e66f85baf">
               <id root="34185cf5-94dc-7039-e063-6394a90a9133"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Phenazopyridine Hydrochloride, USP is light or dark red to dark violet, odorless, slightly bitter, crystalline powder. It has a specific local analgesic effect in the urinary tract, promptly relieving burning and pain. It has the following structural formula:</paragraph>
                  <paragraph> 
 
  <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph> C
 
  <sub>11</sub>H
 
  <sub>11</sub>N
 
  <sub>5</sub>•HCl                                                             M.W. 249.70

 </paragraph>
                  <paragraph>Phenazopyridine HCl tablets, USP contain the following inactive ingredients: carnauba wax, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, pregelatinized starch.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>chem structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="phenazopyridine-hydrochloride-tablets-usp-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_66db959f-1656-49b9-96c8-ec668287a6fe">
               <id root="34185cf5-94dd-7039-e063-6394a90a9133"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <text>
                  <paragraph>Phenazopyridine HCl is excreted in the urine where it exerts a topical analgesic effect on the mucosa of the urinary tract. This action helps to relieve pain, burning, urgency and frequency. The precise mechanism of action is not known.</paragraph>
                  <paragraph>The pharmacokinetic properties of Phenazopyridine HCl have not been determined. Phenazopyridine HCl is rapidly excreted by the kidneys, with as much as 66% of an oral dose being excreted unchanged in the urine.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_25619ce0-bf46-4fac-b9f2-9ed25584c163">
               <id root="34185cf5-94de-7039-e063-6394a90a9133"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled.</paragraph>
                  <paragraph>The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed 2 days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after 2 days (see
 
  <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_da904afa-ab16-49d5-8407-b59636b09d2a">DOSAGE AND ADMINISTRATION</linkHtml>
                     </content> section).

 </paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3c63b350-0da4-4a34-b108-e2a57c0e9159">
               <id root="34185cf5-94df-7039-e063-6394a90a9133"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Phenazopyridine HCl should not be used in patients who have previously exhibited hypersensitivity to it. The use of Phenazopyridine HCl is contraindicated in patients with renal insufficiency.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3ba44916-95ff-4b4c-a2c3-1d3d4e2d1997">
               <id root="34185cf5-94e0-7039-e063-6394a90a9133"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>Headache, rash, pruritus and occasional gastrointestinal disturbance. An anaphylactoid-like reaction has been described. Methemoglobinemia, hemolytic anemia, renal and hepatic toxicity have been reported, usually at overdosage levels (see 
 
  <content styleCode="bold">
                        <linkHtml href="#www.splportal.comLINK_b0e8aca0-d9d5-4193-9fa3-209e2bc24acb">OVERDOSAGE</linkHtml>
                     </content> section).

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4a1b131f-657f-41b1-9cec-9e956c4de21b">
               <id root="34185cf5-94e1-7039-e063-6394a90a9133"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">PRECAUTIONS</content>
               </title>
               <effectiveTime value="20241030"/>
               <component>
                  <section ID="LINK_abbe0fff-6d41-4dc6-83d6-dfb695e38084">
                     <id root="34185cf5-94e2-7039-e063-6394a90a9133"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="bold">General</content>
                     </title>
                     <text>
                        <paragraph>A yellowish tinge of the skin or sclera may indicate accumulation due to impaired renal excretion and the need to discontinue therapy. The decline in renal function associated with advanced age should be kept in mind.</paragraph>
                        <paragraph>NOTE: Patients should be informed that Phenazopyridine HCl produces a reddish-orange discoloration of the urine and may stain fabric. Staining of contact lenses has been reported.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_01da0f4a-1a60-4768-a8c1-f662302e949f">
                     <id root="34185cf5-94e3-7039-e063-6394a90a9133"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>
                        <content styleCode="bold">Laboratory Test Interaction</content>
                     </title>
                     <text>
                        <paragraph>Due to its properties as an azo dye, Phenazopyridine HCl may interfere with urinalysis based on spectrometry or color reactions.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_46157d23-1c85-4e26-9fc1-a119f4ec70f6">
                     <id root="34185cf5-94e4-7039-e063-6394a90a9133"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Carcinogenicity, Mutagenicity, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Long-term administration of Phenazopyridine HCl has induced neoplasia in rats (large intestine) and mice (liver).</paragraph>
                        <paragraph>Although no association between Phenazopyridine HCl and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_44e27052-962c-4f6f-b107-cb6272901d51">
                     <id root="34185cf5-94e5-7039-e063-6394a90a9133"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>Reproduction studies have been performed in rats at doses up to 50 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to Phenazopyridine HCl. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_aa74a1b3-003a-4e74-9c34-1a0b45ae0ab6">
                     <id root="34185cf5-94e6-7039-e063-6394a90a9133"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>
                        <content styleCode="bold">Nursing Mothers</content>
                     </title>
                     <text>
                        <paragraph>No information is available on the appearance of Phenazopyridine HCl, or its metabolites in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5b97eb74-490b-4e8c-ae3e-271e3e0a892f">
               <id root="34185cf5-94e7-7039-e063-6394a90a9133"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph>100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.</paragraph>
                  <paragraph>200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.</paragraph>
                  <paragraph>When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_59a058dd-1686-4b38-bed8-2efc1f4764ff">
               <id root="34185cf5-94e8-7039-e063-6394a90a9133"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Exceeding the recommended dose in patients with good renal function or administering the usual dose to patients with impaired renal function (common in elderly patients) may lead to increased serum levels and toxic reactions. Methemoglobinemia generally follows a massive, acute overdose. Methylene blue, 1 to 2 mg/kg/body weight intravenously or ascorbic acid 100 to 200 mg given orally should cause prompt reduction of the methemoglobinemia and disappearance of the cyanosis which is an aid in diagnosis. Oxidative Heinz body hemolytic anemia may also occur, and “bite cells” (degmacytes) may be present in a chronic overdosage situation. Red blood cell G-6-PD deficiency may predispose to hemolysis. Renal and hepatic impairment and occasional failure, usually due to hypersensitivity, may also occur.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b1cc383f-b406-4765-b699-30f267973013">
               <id root="34185cf5-94e9-7039-e063-6394a90a9133"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">HOW SUPPLIED</content>
               </title>
               <text>
                  <paragraph>Phenazopyridine HCl tablets, USP 
 
  <content styleCode="bold">100 mg</content> are available as deep brown to maroon colored, round, film-coated tablets debossed “PY” above “1” on one side and plain on the other.  
  <br/>  They are supplied as follows:

 </paragraph>
                  <paragraph>Bottles of 6             NDC 72789-362-06</paragraph>
                  <paragraph>
                     <content styleCode="bold">DISPENSE</content> contents with a child-resistant closure (as required) and in a tight container as defined in the USP.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">STORE </content>at 20° to 25°C (68° to 77°F); excursions permitted between15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

 </paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="LINK_135c9923-ce0c-45bb-8cfa-0eea4da5a3d2">
               <id root="34185cf5-94ea-7039-e063-6394a90a9133"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>72789362 Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="72789362.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>